5 Key Takeaways

• 1

  The phase 1 TG-Azercel-101 study evaluated off-the-shelf, donor-derived CD19-directed CAR T-cell therapy in 26 people with progressive multiple sclerosis.

• 2

  All participants had disability progression independent of relapse activity during the prior year despite high-efficacy treatment and had previously received anti-CD20 therapy.

• 3

  After bendamustine lymphodepletion and a single azer-cel infusion, peripheral B-cell counts fell below 10 cells per microliter in 25 of 26 participants.

• 4

  Among 21 participants with paired cerebrospinal fluid samples, median CD19-positive B-cell events declined by 52.3% at day 10.

• 5

  At day 90, disability scores were stable or improved in 16 of 18 evaluable participants; no dose-limiting toxicities or grade 3 or higher cytokine release syndrome were reported.